1. The Phase Ib/II Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL - ClinicalTrials.gov indentifier NCT02158091.
1. A Phase Ib/II Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL. ClinicalTrials.gov identifier NCT02158091.